Condition: Vogt Koyanagi Harada Disease · Sponsor: University of Sao Paulo
This prospective study will include patients with Vogt-Koyanagi-Harada disease from disease onset, treated with early systemic high-dose corticosteroid and immunosuppressive therapy. Clinical and subclinical signs of disease activity added with electroretinogram exams, through predefined intervals, will be evaluated through a minimum 12-month follow-up.
This description comes directly from the study's public registry record.
Joyce H Yamamoto, MD · 55-11-99266-6474 · joycehy@uol.com.br
Always discuss trial participation with your own doctor first.
| Hospital das Clinicas HCFMUSP, Faculdade de Medicina Universidade de Sao Paulo | São Paulo, São Paulo, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03399175